Amerikanische Gesellschaft für Hirudotherapie

Rosacea (Papulopustular Subtype)

Investigational adjunct for papulopustular rosacea subtype with persistent inflammatory lesions; small case series.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for rosacea. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for papulopustular rosacea is investigational.
Welche Evidenz existiert?
Tier C (investigational). One small case series (Wollina 2018 n=18) reports Investigator Global Assessment improvement of 1-2 grades at 12 weeks; there are no randomized controlled trials. Evidence-based therapy per AAD and 2017 ROSCO consensus: topical metronidazole, ivermectin, azelaic acid, or oral doxycycline (sub-antimicrobial 40 mg modified-release). Brimonidine for persistent erythema. Pulsed dye laser or IPL for telangiectasias.
Hauptrisiken
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Worsening of facial erythema or flushing in the short term
  • Post-inflammatory hyperpigmentation, especially in darker Fitzpatrick skin
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Permanent small scars at bite sites on the face
  • Trigger of ocular rosacea if leech placed near eyelids
  • Delay of evidence-based topical or oral therapy
Wer dies nicht in Betracht ziehen sollte
  • Patients with ocular rosacea (specialty management required)
  • Patients with phymatous rosacea (laser ablation or surgical management)
  • Patients with rosacea fulminans (oral isotretinoin or systemic steroid)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients with darker Fitzpatrick skin types at high PIH risk
  • Pregnant patients
  • Patients who have not been offered topical metronidazole, ivermectin, or oral doxycycline
Was Sie Ihren Kliniker fragen sollten
  • Have I tried topical metronidazole, ivermectin, or azelaic acid for at least 12 weeks?
  • Am I a candidate for sub-antimicrobial doxycycline 40 mg modified-release?
  • Should I see an ophthalmologist for ocular rosacea symptoms?
  • Will leech placement risk worsening my flushing or burning?
  • What is the practitioner's experience with facial leech placement and PIH prevention?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the cost and is it covered by insurance? (typically not covered)
Wann dringende medizinische Versorgung suchen
  • Severe sudden facial swelling with fever (rosacea fulminans — emergency)
  • New eye pain, blurred vision, or red painful eye (ocular rosacea)
  • Spreading redness, warmth, pus, or red streaks on the face (cellulitis)
  • Bleeding from a bite site lasting more than 24 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • This is NOT FDA-cleared for rosacea.
  • A single n=18 case series does NOT establish efficacy versus topical ivermectin, metronidazole, or sub-antimicrobial doxycycline.
  • It does NOT mean facial leech application is risk-free — pigment changes and scarring are facial-cosmetic concerns.
  • It does NOT substitute for evidence-based topical or oral therapy.
  • It does NOT address ocular rosacea or phymatous changes, which require specialty care.

Clinical Profile

Category
dermatological
ICD-10
L71.0, L71.8, L71.9
Safety tier
medium

Evidence Summary

The papulopustular rosacea subtype (per the 2017 ROSCO consensus) is conventionally treated with topical metronidazole, ivermectin, azelaic acid, or oral doxycycline (sub-antimicrobial 40 mg). No controlled clinical trial or published efficacy case series of leech therapy for rosacea has been reported; any use is investigational and mechanistic only. This entry is distinct from the registry's primary rosacea entry, which addresses erythematotelangiectatic disease. Post-inflammatory hyperpigmentation risk requires careful patient selection.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Wollina U (2018), n=18

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Ocular rosacea with active blepharitis or keratitis
  • Rhinophyma stage requiring surgical management
  • Patients with darker Fitzpatrick types at high PIH risk

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Rosacea (Papulopustular Subtype) — Hirudotherapy Evidence | ASH